Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAM-103 in healthy subjects
NCT07304791Phase 1Recruiting
- Sponsor
- Beam Therapeutics
- Start
- Oct 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial comparing BEAM-103 Drug Product with Placebo (2 arms). Primary endpoint: Safety and Tolerability of Single Ascending Doses of BEAM-103 at 5 months. Started Oct 2025; status: recruiting.
02
Drugs
BEAM-103
Beyond the preview
Go deeper on NCT07304791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07304791.